S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK

• Efstathios Kastritis,
• Giovanni Palladini,
• Meletios A. Dimopoulos,
• Arnaud Jaccard,
• Giampaolo Merlini,
• Foteini Theodorakakou,
• Despina Fotiou,
• Monique C. Minnema Minnema,
• Ashutosh Wechalekar,
• Elena Papachristou,
• Kyriaki Manousou,
• Pieter Sonneveld,
• Stefan Schönland

Affiliations

Efstathios Kastritis

1 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

Giovanni Palladini

2 Amyloidosis Research and Treatment Center, University of Pavia, Pavia, Italy

Meletios A. Dimopoulos

1 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

Arnaud Jaccard

3 Referral Center for AL Amyloidosis, Limoges, France

Giampaolo Merlini

2 Amyloidosis Research and Treatment Center, University of Pavia, Pavia, Italy

Foteini Theodorakakou

1 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

Despina Fotiou

1 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

Monique C. Minnema Minnema

4 Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands

Ashutosh Wechalekar

5 Clinical Haematology, Cancer Division, University College London Hospital, London, UK

Elena Papachristou

6 Health Data Specialists, Dublin, Ireland

Kyriaki Manousou

6 Health Data Specialists, Dublin, Ireland

Pieter Sonneveld

7 Erasmus MC Cancer Institute, Rotterdam, Netherlands

Stefan Schönland

8 University of Heidelberg, Heidelberg, Germany